SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
-4.67%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$268M
AUM Growth
+$268M
(-25%)
Cap. Flow
-$63.4M
Cap. Flow
% of AUM
-23.67%
Top 10 Holdings %
Top 10 Hldgs %
61.83%
Holding
30
New
2
Increased
4
Reduced
22
Closed
2
Top Buys
| 1 |
Gilead Sciences
GILD
|
$10.6M |
| 2 |
Amgen
AMGN
|
$9.37M |
| 3 |
Abbott
ABT
|
$7.27M |
| 4 |
Bristol-Myers Squibb
BMY
|
$1.51M |
| 5 |
Centene
CNC
|
$1.51M |
Top Sells
| 1 |
Medtronic
MDT
|
$11.6M |
| 2 |
Pfizer
PFE
|
$9.63M |
| 3 |
Cardinal Health
CAH
|
$7.42M |
| 4 |
Universal Health Services
UHS
|
$6.45M |
| 5 |
Globus Medical
GMED
|
$5.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $28.8M | 10.77% |
420,163
+154,544
| +58% | +$10.6M |
|
|
2
Pfizer
PFE
$141B
| $25M | 9.36% |
895,000
-344,165
| -28% | -$9.63M |
|
|
3
Bristol-Myers Squibb
BMY
$96B
| $22.2M | 8.3% |
535,000
+36,464
| +7% | +$1.51M |
|
|
4
Medtronic
MDT
$119B
| $20.8M | 7.79% |
264,890
-147,003
| -36% | -$11.6M |
|
5
Elevance Health
ELV
$71.8B
| $13.2M | 4.91% |
24,279
-10,018
| -29% | -$5.43M |
|
6
CVS Health
CVS
$92.8B
| $13M | 4.85% |
220,000
-88,004
| -29% | -$5.2M |
|
7
Incyte
INCY
$16.5B
| $12.3M | 4.61% |
203,376
-61,519
| -23% | -$3.73M |
|
|
8
Cardinal Health
CAH
$35.5B
| $10.5M | 3.93% |
107,098
-75,489
| -41% | -$7.42M |
|
9
Biogen
BIIB
$19.4B
| $10.2M | 3.81% |
43,985
-15,713
| -26% | -$3.64M |
|
|
10
Amgen
AMGN
$155B
| $9.37M | 3.5% |
+30,000
| New | +$9.37M |
|
11
Zimmer Biomet
ZBH
$21B
| $9.23M | 3.45% |
85,000
-36,033
| -30% | -$3.91M |
|
12
Baxter International
BAX
$12.7B
| $8.7M | 3.25% |
260,000
-63,120
| -20% | -$2.11M |
|
13
GE HealthCare
GEHC
$33.7B
| $8.1M | 3.03% |
104,000
-19,133
| -16% | -$1.49M |
|
14
Ionis Pharmaceuticals
IONS
$6.79B
| $8.1M | 3.03% |
170,000
-5,507
| -3% | -$262K |
|
15
Bruker
BRKR
$5.16B
| $7.37M | 2.75% |
115,472
+2,697
| +2% | +$172K |
|
|
16
Abbott
ABT
$231B
| $7.27M | 2.72% |
+70,000
| New | +$7.27M |
|
17
Tenet Healthcare
THC
$16.3B
| $7.03M | 2.63% |
52,861
-24,674
| -32% | -$3.28M |
|
|
18
Universal Health Services
UHS
$11.6B
| $6.47M | 2.42% |
35,000
-34,881
| -50% | -$6.45M |
|
19
Edwards Lifesciences
EW
$47.8B
| $6.39M | 2.39% |
69,153
-37,713
| -35% | -$3.48M |
|
20
Agios Pharmaceuticals
AGIO
$2.19B
| $5.25M | 1.96% |
121,844
-42,534
| -26% | -$1.83M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $5.22M | 1.95% |
63,348
-18,068
| -22% | -$1.49M |
|
22
Alkermes
ALKS
$4.78B
| $4.68M | 1.75% |
194,000
-58,319
| -23% | -$1.41M |
|
23
Bio-Rad Laboratories Class A
BIO
$8.06B
| $4.6M | 1.72% |
16,829
-16,833
| -50% | -$4.6M |
|
24
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.7M | 1.38% |
15,240
-12,343
| -45% | -$3M |
|
25
Qiagen
QGEN
$10.1B
| $3.43M | 1.28% |
83,484
-19,885
| -19% | -$817K |
|